中华心血管病杂志
中華心血管病雜誌
중화심혈관병잡지
Chinese Journal of Cardiology
2013年
4期
301-303
,共3页
贾坦%张李军%战义强%余金明%胡大一
賈坦%張李軍%戰義彊%餘金明%鬍大一
가탄%장리군%전의강%여금명%호대일
高血压%氨氯地平%随机对照试验
高血壓%氨氯地平%隨機對照試驗
고혈압%안록지평%수궤대조시험
Hypertension%Amlodipine%Randomized controlled trials
目的 评价苯磺酸左旋氨氯地平(左旋氨氯地平)治疗轻、中度原发性高血压的疗效和安全性.方法 采用随机、开放、平行对照的方法,从22个研究中心选取1051例轻、中度原发性高血压患者,分别给予低剂量左旋氨氯地平(2.5 mg/d,左旋氨氯地平2.5 mg组),高剂量左旋氨氯地平(5.0 mg/d,左旋氨氯地平5.0 mg组)和马来酸氨氯地平(5.0 mg/d,马来酸氨氯地平组)治疗8周,观察其疗效和安全性.结果 左旋氨氯地平2.5 mg组、左旋氨氯地平5.0 mg组和马来酸氨氯地平组入选高血压患者分别为351、350和350例,完成8周治疗的患者分别为322、312和303例,收缩压和舒张压均显著下降,血压达标率分别为72.4%、85.6%和76.2%.左旋氨氯地平5.0 mg组的达标率高于马来酸氨氯地平组和左旋氨氯地平2.5 mg组,差异均有统计学意义(P均<0.01),而左旋氨氯地平2.5 mg组和马来酸氨氯地平5.0 mg组组间差异无统计学意义(P=0.28).在轻度和中度高血压患者中,左旋氨氯地平5.0 mg组达标率也显著高于其他两组.三组不良反应发生率分别为4.3%、4.6%和5.1%,差异无统计学意义(P=0.84).结论 左旋氨氯地平5.0 mg/d治疗原发性高血压疗效优于马来酸氨氯地平5.0 mg/d和左旋氨氯地平2.5 mg/d,左旋氨氯地平2.5 mg/d的疗效与马来酸氨氯地平5.0 mg/d的疗效相当,它们的安全性良好.
目的 評價苯磺痠左鏇氨氯地平(左鏇氨氯地平)治療輕、中度原髮性高血壓的療效和安全性.方法 採用隨機、開放、平行對照的方法,從22箇研究中心選取1051例輕、中度原髮性高血壓患者,分彆給予低劑量左鏇氨氯地平(2.5 mg/d,左鏇氨氯地平2.5 mg組),高劑量左鏇氨氯地平(5.0 mg/d,左鏇氨氯地平5.0 mg組)和馬來痠氨氯地平(5.0 mg/d,馬來痠氨氯地平組)治療8週,觀察其療效和安全性.結果 左鏇氨氯地平2.5 mg組、左鏇氨氯地平5.0 mg組和馬來痠氨氯地平組入選高血壓患者分彆為351、350和350例,完成8週治療的患者分彆為322、312和303例,收縮壓和舒張壓均顯著下降,血壓達標率分彆為72.4%、85.6%和76.2%.左鏇氨氯地平5.0 mg組的達標率高于馬來痠氨氯地平組和左鏇氨氯地平2.5 mg組,差異均有統計學意義(P均<0.01),而左鏇氨氯地平2.5 mg組和馬來痠氨氯地平5.0 mg組組間差異無統計學意義(P=0.28).在輕度和中度高血壓患者中,左鏇氨氯地平5.0 mg組達標率也顯著高于其他兩組.三組不良反應髮生率分彆為4.3%、4.6%和5.1%,差異無統計學意義(P=0.84).結論 左鏇氨氯地平5.0 mg/d治療原髮性高血壓療效優于馬來痠氨氯地平5.0 mg/d和左鏇氨氯地平2.5 mg/d,左鏇氨氯地平2.5 mg/d的療效與馬來痠氨氯地平5.0 mg/d的療效相噹,它們的安全性良好.
목적 평개분광산좌선안록지평(좌선안록지평)치료경、중도원발성고혈압적료효화안전성.방법 채용수궤、개방、평행대조적방법,종22개연구중심선취1051례경、중도원발성고혈압환자,분별급여저제량좌선안록지평(2.5 mg/d,좌선안록지평2.5 mg조),고제량좌선안록지평(5.0 mg/d,좌선안록지평5.0 mg조)화마래산안록지평(5.0 mg/d,마래산안록지평조)치료8주,관찰기료효화안전성.결과 좌선안록지평2.5 mg조、좌선안록지평5.0 mg조화마래산안록지평조입선고혈압환자분별위351、350화350례,완성8주치료적환자분별위322、312화303례,수축압화서장압균현저하강,혈압체표솔분별위72.4%、85.6%화76.2%.좌선안록지평5.0 mg조적체표솔고우마래산안록지평조화좌선안록지평2.5 mg조,차이균유통계학의의(P균<0.01),이좌선안록지평2.5 mg조화마래산안록지평5.0 mg조조간차이무통계학의의(P=0.28).재경도화중도고혈압환자중,좌선안록지평5.0 mg조체표솔야현저고우기타량조.삼조불량반응발생솔분별위4.3%、4.6%화5.1%,차이무통계학의의(P=0.84).결론 좌선안록지평5.0 mg/d치료원발성고혈압료효우우마래산안록지평5.0 mg/d화좌선안록지평2.5 mg/d,좌선안록지평2.5 mg/d적료효여마래산안록지평5.0 mg/d적료효상당,타문적안전성량호.
Objective To evaluate the effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension.Method A total of 1051 mild to moderate essential hypertensives were recruited from 22 centers and randomized into three groups and were given low-dose L-amlodipine besylate (2.5 mg/d),high-dose L-amlodipine besylate (5.0 mg/d),and amlodipine maleate (5.0 mg/d) on the principle of open-label and parallel control.The study drugs were administered for 8 weeks.Results After 8 weeks treatments,the response rate of the three groups were 72.4%,85.6%,and 76.2%,respectively.The rate difference between high-dose L-amlodipine besylate group and the other two groups were statistically significant (P < 0.01),while the rate difference between low-dose L-amlodipine besylate group and amlodipine maleate group was similar (P =0.28).The event rates of the three groups were similar (4.3%,4.6%,and 5.1%,respectively,P =0.84).Conclusion High-dose L-amlodipine besylate is superior to the other 2 groups on blood pressure control.The efficacy profiles of amlodipine maleate and low-dose L-amlodipine besylate are equivalent.Safety profiles of these three groups are comparable.